159 related articles for article (PubMed ID: 23249603)
1. Correlation between a short-term intravenous octreotide suppression test and response to antrectomy in patients with type-1 gastric neuroendocrine tumours.
Murugesan SV; Steele IA; Dimaline R; Poston GJ; Shrotri M; Campbell F; Varro A; Pritchard DM
Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):474-81. PubMed ID: 23249603
[TBL] [Abstract][Full Text] [Related]
2. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
3. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
4. Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor.
Higham AD; Dimaline R; Varro A; Attwood S; Armstrong G; Dockray GJ; Thompson DG
Gastroenterology; 1998 Apr; 114(4):817-22. PubMed ID: 9516403
[TBL] [Abstract][Full Text] [Related]
5. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors.
Dakin GF; Warner RR; Pomp A; Salky B; Inabnet WB
J Surg Oncol; 2006 Apr; 93(5):368-72. PubMed ID: 16550587
[TBL] [Abstract][Full Text] [Related]
6. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
Boyce M; Moore AR; Sagatun L; Parsons BN; Varro A; Campbell F; Fossmark R; Waldum HL; Pritchard DM
Br J Clin Pharmacol; 2017 Mar; 83(3):466-475. PubMed ID: 27704617
[TBL] [Abstract][Full Text] [Related]
7. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
Khuroo MS; Khuroo MS; Khuroo NS
J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
[TBL] [Abstract][Full Text] [Related]
8. [Gastric carcinoid tumours. Is there a place for antrectomy?].
Guillem P
Ann Chir; 2005 Jun; 130(5):323-6. PubMed ID: 15890310
[TBL] [Abstract][Full Text] [Related]
9. [Fundic endocrine tumors and atrophic gastritis: the value of antrectomy].
Guillem P; Vlaeminck-Guillem V; Leteurtre E; Kornhauser R; Cortot A; Wemeau JL; Triboulet JP
Gastroenterol Clin Biol; 2002; 26(8-9):782-5. PubMed ID: 12434081
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours.
Min BH; Hong M; Lee JH; Rhee PL; Sohn TS; Kim S; Kim KM; Kim JJ
Br J Surg; 2018 Oct; 105(11):1480-1486. PubMed ID: 29893418
[TBL] [Abstract][Full Text] [Related]
11. Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report.
Eckhauser FE; Lloyd RV; Thompson NW; Raper SE; Vinik AI
Surgery; 1988 Dec; 104(6):1046-53. PubMed ID: 3194832
[TBL] [Abstract][Full Text] [Related]
12. Gastric carcinoid tumours associated with hypergastrinaemia and pernicious anaemia--regression of tumors by antrectomy. A case report.
Richards AT; Hinder RA; Harrison AC
S Afr Med J; 1987 Jul; 72(1):51-3. PubMed ID: 3603295
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of laparoscope-assisted antrectomy for gastric carcinoids with hypergastrinemia.
Hoshino M; Omura N; Yano F; Tsuboi K; Matsumoto A; Yamamoto SR; Akimoto S; Kashiwagi H; Yanaga K
Hepatogastroenterology; 2010; 57(98):379-82. PubMed ID: 20583448
[TBL] [Abstract][Full Text] [Related]
14. Gastrin production following antrectomy. A study on the occurrence of gastrin-producing cells and the serum gastrin response to feeding.
Nielsen HO; Lauritsen K; Hansen MG; Christiansen LA
Acta Pathol Microbiol Immunol Scand A; 1983 May; 91(3):161-4. PubMed ID: 6858687
[TBL] [Abstract][Full Text] [Related]
15. Treatment of ECL cell carcinoids with octreotide LAR.
Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
[TBL] [Abstract][Full Text] [Related]
16. Oxyntic endocrine cells of hypergastrinaemic patients. Differential response to antrectomy or octreotide.
D'Adda T; Annibale B; Delle Fave G; Bordi C
Gut; 1996 May; 38(5):668-74. PubMed ID: 8707110
[TBL] [Abstract][Full Text] [Related]
17. Extended octreotide suppression test to determine hormone responsiveness of multiple type I gastric carcinoid tumors.
Fayyaz M; Mehboob S; Andersen V; Sitrin MD
Dig Dis Sci; 2007 Jun; 52(6):1579-85. PubMed ID: 17429721
[TBL] [Abstract][Full Text] [Related]
18. Antrectomy and gastroduodenostomy with or without vagotomy in peptic ulcer disease. A prospective study with a 5-year follow-up.
Rehnberg O
Acta Chir Scand Suppl; 1983; 515():1-63. PubMed ID: 6579806
[TBL] [Abstract][Full Text] [Related]
19. Gastric neuroendocrine tumours.
Crosby DA; Donohoe CL; Fitzgerald L; Muldoon C; Hayes B; O'Toole D; Reynolds JV
Dig Surg; 2012; 29(4):331-48. PubMed ID: 23075625
[TBL] [Abstract][Full Text] [Related]
20. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.
Ramundo V; Del Prete M; Marotta V; Marciello F; Camera L; Napolitano V; De Luca L; Circelli L; Colantuoni V; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A;
Clin Endocrinol (Oxf); 2014 Jun; 80(6):850-5. PubMed ID: 24443791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
